We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Cytokine Concentration Linked to Chronic Fatigue Syndrome

By LabMedica International staff writers
Posted on 16 Aug 2017
Print article
Image: The Luminex 200 multiplex analyzer (Photo courtesy of Luminex Corporation).
Image: The Luminex 200 multiplex analyzer (Photo courtesy of Luminex Corporation).
More than one million people in the USA suffer from chronic fatigue syndrome, also known as myalgic encephomyelitis and designated by the acronym ME/CFS. It is a disease with no known cure or even reliably effective treatments.

Three of every four ME/CFS patients are women, for reasons that are not understood. It characteristically arises in two major waves: among adolescents between the ages of 15 and 20, and in adults between 30 and 35. The condition typically persists for decades.

Scientists at Stanford University School of Medicine (Stanford, CA, USA) analyzed blood samples from 192 patients with ME/CFS, as well as from 392 healthy control subjects. The average age of patients and controls was about 50. Patients' average duration of symptoms was somewhat more than 10 years. Antivirals, anti-inflammatories and immune-modulating drugs had led to symptomatic improvement in some cases, but no single pathogenic agent that can be fingered as the ultimate ME/CFS trigger has yet been isolated.

To determine whether a signature of serum cytokines could be associated with ME/CFS and correlated with disease severity and fatigue duration, cytokines of the ME/CFS patients and the healthy controls were measured using a 51-multiplex array on Luminex 200 IS system. Each cytokine’s preprocessed data were regressed on ME/CFS severity plus covariates for age, sex, race, and an assay property of newly discovered importance: nonspecific binding.

The investigators reported that when comparing patients versus control subjects, they found that only two of the 51 cytokines they measured were different. Tumor growth factor beta (TGF-β) was higher and resistin was lower in ME/CFS patients. However, they found that the concentrations of 17 of the cytokines tracked disease severity, and 13 of those 17 cytokines are pro-inflammatory. One of the cytokines whose levels corresponded to disease severity, leptin, is secreted by fat tissue. Best known as a satiety reporter that tells the brain when somebody's stomach is full, leptin is also an active pro-inflammatory substance. Generally, leptin is more abundant in women's blood than in men's, which could throw light on why more women than men have ME/CFS.

Jose G. Montoya, MD, professor of infectious diseases, and lead author of the study, said, “Chronic fatigue syndrome can turn a life of productive activity into one of dependency and desolation. For decades, the 'case versus healthy controls' study design has served well to advance our understanding of many diseases. However, it's possible that for certain pathologies in humans, analysis by disease severity or duration would be likely to provide further insight.” The study was published on July 31, 2017, in the journal Proceedings of the National Academy of Sciences.

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Urine Drug Test
Instant-view Ecstasy (MDMA)
New
Uric Acid and Blood Glucose Meter
URIT-10

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.